
Bone Therapeutics appoints Pfizer veteran
pharmafile | November 28, 2014 | Appointment | |Â Â Â
Belgium-based biotech Bone Therapeutics has appointed Dr Guy Heynen as its new chief clinical and regulatory officer.
Heynen is a specialist in rheumatology and immunology, with experience both in university medical practice and in the pharmaceutical industry. He has over 35 years’ experience in medical and regulatory affairs at local, regional and international levels and has a particular focus on management and leadership.
The majority of his career has been with Pfizer where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer’s disease drug, Aricept, and medical team leader for Pfizer’s anti-inflammatory drug franchise based in New York.
Heynen also serves on the boards of Euroscreen, Progenosis and as an advisor for Promethera Biosciences. He also remains a regional medical monitor for Pfizer GmbH.
Enrico Bastianelli, chief executive of Bone Therapeutics says of Heynen: “His long-standing experience within major pharmaceutical companies around the world will be key in preparing to bring our products to market and supporting Bone Therapeutics’ development on a global scale. Dr Heynen’s experience advising cell therapy companies also provides important understanding of this growing sector.”






